Dr. Jonathan E. Brammer, MD
Claim this profileOhio State University Comprehensive Cancer Center
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Cancer
8 reported clinical trials
18 drugs studied
Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
CD3 positive
TCR positive
NK-cell population positive
2Cancer
Stage IV
CD3 positive
CD2 positive
Affiliated Hospitals
Clinical Trials Jonathan E. Brammer, MD is currently running
Lenalidomide + EPOCH Chemotherapy
for Adult T-Cell Leukemia-Lymphoma
This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate \[Oncovin\], cyclophosphamide, and doxorubicin hydrochloride \[hydroxydaunorubicin hydrochloride\], or "EPOCH") in treating adult T-cell leukemia-lymphoma. Lenalidomide may help shrink or slow the growth of adult T-cell leukemia-lymphoma. Drugs used in chemotherapy, such as etoposide, vincristine, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving lenalidomide and the usual combination chemotherapy may work better in treating adult T-cell leukemia-lymphoma compared to the usual combination chemotherapy alone.
Recruiting1 award Phase 1
Oral Azacitidine
for Leukemia
This trial studies the best dose and effects of oral azacitidine in patients with T-cell large granular lymphocytic leukemia that has come back or did not respond to previous treatments. Azacitidine is a chemotherapy drug that stops cancer cells from growing, dividing, or spreading.
Recruiting1 award Phase 1 & 215 criteria
More about Jonathan E. Brammer, MD
Clinical Trial Related3 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Jonathan E. Brammer, MD has experience with
- Prednisone
- Duvelisib
- Oral Azacitidine
- Ruxolitinib
- NEXI-001 T Cell Product
- Lenalidomide
Breakdown of trials Jonathan E. Brammer, MD has run
T-Lymphoblastic Leukemia/Lymphoma
Cancer
Lymphoid Leukemia
T-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jonathan E. Brammer, MD specialize in?
Jonathan E. Brammer, MD focuses on T-Lymphoblastic Leukemia/Lymphoma and Cancer. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved CD3 positive patients, or patients who are TCR positive.
Is Jonathan E. Brammer, MD currently recruiting for clinical trials?
Yes, Jonathan E. Brammer, MD is currently recruiting for 5 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Jonathan E. Brammer, MD has studied deeply?
Yes, Jonathan E. Brammer, MD has studied treatments such as Prednisone, Duvelisib, Oral Azacitidine.
What is the best way to schedule an appointment with Jonathan E. Brammer, MD?
Apply for one of the trials that Jonathan E. Brammer, MD is conducting.
What is the office address of Jonathan E. Brammer, MD?
The office of Jonathan E. Brammer, MD is located at: Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States. This is the address for their practice at the Ohio State University Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.